Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review

References

• Silberstein SD. Current management: migraine headache. CNS Spectr. 2017;22:1–13.
   PubMed Web of Science ®Google Scholar
• Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211. doi:10.1177/0333102417738202.
   PubMed Web of Science ®Google Scholar
• Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav. 2018;8:e00950.
   PubMed Web of Science ®Google Scholar
• Speck V, Maihöfner C. Migraine- established concepts and new developments. Fortschr Neurol Psychiatr. 2013;81:308–323.
   PubMed Web of Science ®Google Scholar
• Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8:679–690.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.
   PubMed Web of Science ®Google Scholar
• Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol. 2006;95:1298–1306.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15:483–490.
   PubMed Web of Science ®Google Scholar
• Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703–1709.
   PubMed Web of Science ®Google Scholar
• Waschek JA, Baca SM, Akerman S. PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain. 2018;19:23. doi:10.1186/s10194-018-0850-6.
   Web of Science ®Google Scholar
• Gross EC, Lisicki M, Fischer D, et al. The metabolic face of migraine-from pathophysiology to treatment. Nat Rev Neurol. 2019;15:627–643.
   PubMed Web of Science ®Google Scholar
• Haanes KA, Edvinsson L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs. 2019;33:525–537.
   PubMed Web of Science ®Google Scholar
• Kimura C, Ohkubo S, Ogi K, et al. A novel peptide which stimulates adenylate cyclase: molecular cloning and characterization of the ovine and human cDNAs. Biochem Biophys Res Commun. 1990;166:81–89.
   PubMed Web of Science ®Google Scholar
• Hirabayashi T, Nakamachi T, Shioda S. Discovery of PACAP and its receptors in the brain. J Headache Pain. 2018;19:28.
   PubMed Web of Science ®Google Scholar
• Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61:283–357.
   PubMed Web of Science ®Google Scholar
• Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther. 2009;121:294–316.
   PubMed Web of Science ®Google Scholar
• Amin FM, Schytz HW. Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. J Headache Pain. 2018;19:35.
   PubMed Web of Science ®Google Scholar
• Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012;166:4–17.
   PubMed Web of Science ®Google Scholar
• Laburthe M, Couvineau A, Class TV. II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides. 2007;28:1631–1639.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltrán E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018;19:64.
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Möller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76:176–183.
   PubMedGoogle Scholar
• Uddman R, Tajti J, Hou M, et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia. 2002;22:112–116.
   PubMed Web of Science ®Google Scholar
• Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides. 2001;22:995–1007.
   PubMed Web of Science ®Google Scholar
• Uddman R, Tajti J, Möller S, et al. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res. 1999;826:193–199.
   PubMed Web of Science ®Google Scholar
• Palkovits M, Somogyvári-Vigh A, Arimura A. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res. 1995;699:116–120.
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the “migraine generator” region of the human brainstem. Cephalalgia. 2001;21:96–101.
   PubMed Web of Science ®Google Scholar
• Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport. 2002;13:507–509.
   PubMed Web of Science ®Google Scholar
• Chan KY, Baun M, De Vries R, et al. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia. 2011;31:181–189.
   PubMed Web of Science ®Google Scholar
• Birk S, Sitarz JT, Petersen KA, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept. 2007;140:185–191.
   PubMedGoogle Scholar
• Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132:16–25.
   PubMed Web of Science ®Google Scholar
• Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 2012;32:140–149.
   PubMed Web of Science ®Google Scholar
• Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137:779–794.
   PubMed Web of Science ®Google Scholar
• Amin FM, Hougaard A, Magon S, et al. Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. Neurology. 2016;86:180–187.
   PubMed Web of Science ®Google Scholar
• Guo S, Vollesen ALH, Olesen J, et al. Premonitory and non headache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain. 2016;157:2773–2781.
   PubMed Web of Science ®Google Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33:1085–1095.
   PubMed Web of Science ®Google Scholar
• Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol. 2014;1:1036–1040.
   PubMed Web of Science ®Google Scholar
• Han X, Ran Y, Su M, et al. Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats. Mol Pain. 2017;13:1–10.
   Web of Science ®Google Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, et al. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia. 2019;39:1735–1744.
   PubMed Web of Science ®Google Scholar
• Ghanizada H, MA-M A-K, Arngrim N, et al. PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia. 2020;40:57–67.
   PubMed Web of Science ®Google Scholar
• Baun M, Pedersen MHF, Olesen J, et al. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia. 2012;32:337–345.
   PubMed Web of Science ®Google Scholar
• Bhatt DK, Gupta S, Olesen J, et al. PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells. Cephalalgia. 2014;34:877–886.
   PubMed Web of Science ®Google Scholar
• Jansen-Olesen I, Hougaard Pedersen SPACAP. and its receptors in cranial arteries and mast cells. J Headache Pain. 2018;19:16.
   PubMed Web of Science ®Google Scholar
• Guo S, Vollesen ALH, Hansen YB, et al. Part II: biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia. 2017;37:136–147.
   PubMed Web of Science ®Google Scholar
• Tuka B, Helyes Z, Markovics A, et al. Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides. 2012;33:307–316.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Miller S, Martins-Oliveira M, et al. PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? Pain. 2020. [Epub ahead of print]. DOI:10.1097/j.pain.0000000000001858
   PubMed Web of Science ®Google Scholar
• Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015;7:308ra157.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Malmberg AB, Yaksh TL, et al. Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept. 1997;69:83–87.
   PubMedGoogle Scholar
• Davis-Taber R, Baker S, Lehto SG, et al. Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J Pain. 2008;9:449–456.
   PubMed Web of Science ®Google Scholar
• Liu N-J, Schnell SA, Schulz S, et al. Regulation of spinal dynorphin 1-17 release by endogenous pituitary adenylyl cyclase-activating polypeptide in the male rat: relevance of excitation via disinhibition. J Pharmacol Exp Ther. 2011;336:328–335.
   PubMed Web of Science ®Google Scholar
• Jongsma H, Pettersson LM, Zhang Y, et al. Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. Neuroreport. 2001;12:2215–2219.
   PubMed Web of Science ®Google Scholar
• Moldovan Loomis C, Dutzar B, Ojala EW, et al. Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide. J Pharmacol Exp Ther. 2019;369:26–36.
   PubMed Web of Science ®Google Scholar
• Hensley K, Pretorius J, Chan B, et al. PAC1 receptor mRNA and protein distribution in rat and human trigeminal and sphenopalatine ganglia, spinal trigeminal nucleus and in dura mater. Cephalalgia. 2019;39:827–840.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Baraldi C, Licata M, et al. Polypharmacy among headache patients: a cross-sectional study. CNS Drugs. 2018;32:567–578.
   PubMed Web of Science ®Google Scholar
• Edvinsson JCA, Grell A-S, Warfvinge K, et al. Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system. Cephalalgia. 2020;333102420929026. doi:10.1177/0333102420929026.
   Web of Science ®Google Scholar
• Pradhan AA, Bertels Z, Akerman S. Targeted nitric oxide synthase inhibitors for migraine. Neurotherapeutics. 2018;15:391–401.
   PubMed Web of Science ®Google Scholar
• Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia. 2009;29:124. Abstracts of the European Headache and Migraine Trust International Congress 2008
   Google Scholar
• Conconi MT, Spinazzi R, Nussdorfer GG. Endogenous ligands of PACAP/VIP receptors in the autocrine–paracrine regulation of the adrenal gland. Int Rev Cytol. 2006;249:1–51.
   PubMedGoogle Scholar
• Pellesi L, MA-M A-K, Chaudhry BA, et al. Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia. 2020;333102420937655. doi:10.1177/0333102420929026. [published online ahead of print, 2020 Jun 27]
   Web of Science ®Google Scholar
• Zhang Q, Han X, Wu H, et al. Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: relevant to migraine. Mol Pain. 2019;15:1744806918820452.
   Web of Science ®Google Scholar
• Edvinsson L, Tajti J, Szalárdy L, et al. PACAP and its role in primary headaches. J Headache Pain. 2018;19:21.
   PubMed Web of Science ®Google Scholar
• De Logu F, Landini L, Janal MN, et al. Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain. 2019;20:18.
   PubMed Web of Science ®Google Scholar
• Vécsei L, Lukács M, Tajti J, et al. The therapeutic impact of new migraine discoveries. Curr Med Chem. 2019;26:6261–6281.
   PubMed Web of Science ®Google Scholar
• Körtési T, Tuka B, Nyári A, et al. The effect of orofacial complete Freund’s adjuvant treatment on the expression of migraine-related molecules. J Headache Pain. 2019;20:43.
   PubMed Web of Science ®Google Scholar
• Stroth N, Holighaus Y, Ait-Ali D, et al. PACAP: a master regulator of neuroendocrine stress circuits and the cellular stress response. Ann N Y Acad Sci. 2011;1220:49–59.
   PubMed Web of Science ®Google Scholar
• Lukács M, Warfvinge K, Tajti J, et al. Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). J Headache Pain. 2017;18:39.
   PubMed Web of Science ®Google Scholar
• Reglodi D, Vaczy A, Rubio-Beltran E, et al. Protective effects of PACAP in ischemia. J Headache Pain. 2018;19:19.
   PubMed Web of Science ®Google Scholar
• Hou L, Wan D, Dong Z, et al. Pituitary adenylate cyclase-activating polypeptide expression in peripheral blood mononuclear cells of migraineurs. Cell Biosci. 2016;6:40.
   PubMed Web of Science ®Google Scholar
• Bertels Z, Pradhan AAA. Emerging treatment targets for migraine and other headaches. Headache. 2019;59(Suppl 2):50–65.
   PubMed Web of Science ®Google Scholar
• Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59(Suppl 2):20–32.
   PubMed Web of Science ®Google Scholar
• Pomes LM, Guglielmetti M, Bertamino E, et al. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20:56.
   PubMed Web of Science ®Google Scholar